Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from a trial. The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo….

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from a trial. The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo….